secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sionna Therapeutics, Inc. (SION)
CIK:        0002036042
Form:       8-K
Filed at:   2025-06-04T23:59:59+00:00
Accession:  0001193125-25-134462
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sionna reports positive Phase 1 data for NBD1 stabilizers SION-719 and SION-451; advances both to next trials
--------------------------------------------------------------------------------

- Both SION-719 and SION-451 were generally well tolerated with no serious adverse events or discontinuations.
- Both compounds met exposure thresholds from preclinical CFHBE model, indicating potential for clinically meaningful benefit.
- SION-719 to advance to Phase 2a proof-of-concept add-on trial in CF patients; initiation H2 2025, topline mid-2026.
- SION-451 to advance to Phase 1 dual combination trial with SION-2222 and SION-109; initiation H2 2025, topline mid-2026.
- FDA cleared IND for SION-719; first subject dosed in midazolam drug-drug interaction study.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2036042/000119312525134462/0001193125-25-134462-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2036042/000119312525134462/d944102d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-134462

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer